A cluster of T cells enveloping a cancer cell

Read our September issue

This issue showcases active companies developing therapeutics and technologies focused around antibodies, and to treat oncology. The issue also includes our central nervous system disorders collection

Advertisement

  • With a focus on detecting, intercepting, treating, and ultimately curing cancer, Janssen Oncology is advancing science and solutions in hematologic malignancies and solid tumors through an innovative strategic partnering approach.

    • Janssen Oncology
    Advertisement Feature
  • Hayashibara is exploring the potential of the saccharide, trehalose, to advance progress in the development of new medical and therapeutic applications, with a particular focus on its ability to stabilize exosomes and improve drug delivery.

    • Hayashibara Co., Ltd. / NAGASE Group
    Advertisement Feature
  • Building on its history of successful collaborations, the global business unit at Sanofi responsible for vaccines is seeking partners with a common drive for excellence and pursuit of innovation.

    • Vaccines at Sanofi
    Advertisement Feature
  • Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

    • Synaffix
    Advertisement Feature
  • Precision diagnostics and monitoring company Oncocyte is developing the most comprehensive and rapid tumor-microenvironment gene-expression test to assess immunotherapeutic responsiveness. Combined with the company’s other tests, it provides a complete solution for cancer immunotherapy management and monitoring.

    • Oncocyte Corporation
    Advertisement Feature
  • OncXerna Therapeutics is pioneering the use of artificial intelligence (AI) in the development of drugs and biomarkers for cancer, targeting patients’ tumor microenvironment (TME) to develop a precision-medicine approach that might identify those who will benefit most from the treatments in its pipeline.

    • OncXerna Therapeutics
    Advertisement Feature
  • Marengo Therapeutics’ breakthrough discovery in T cell receptor (TCR) activation blazes a new trail for safe treatment and long-term protection against cancer.

    • Marengo Therapeutics
    Advertisement Feature
Nerve cell

Fighting central nervous system disorders

Discover active companies developing innovative technologies and therapeutics to prevent and treat the diseases of the central nervous system.
Collection

Advertisement